Ann: Appendix 4C - Quarterly, page-15

You've asked a good question there bioqld, when you state "what completion of a commercial deal"?

Either someone at RGS who crafted the Appendix 4C Quarterly report was very sloppy with their tense, or was being super tricky where the report states that "the completion of a commercial deal allows Regeneus to be sufficiently funded to commercialisation in Japan" That section of the report should say "would allow" or "will allow".

In any case, all will surely have to be revealed by Regeneus within days or weeks, because I can't see how the ASX can be a spectator when the Appendix 4 C quarterly report clearly shows that with cash running out by late March and with the $1.1 million loan by certain Directors' due for repayment at an unspecified point during March, there is otherwise a real risk that a continuation of the status quo could bring Regeneus to the brink of insolvency.

zeno9